期刊文献+

全身伽玛刀配合化疗治疗局部晚期非小细胞肺癌的近期疗效观察 被引量:5

下载PDF
导出
摘要 目的观察全身伽玛刀配合化疗治疗局部晚期非小细胞肺癌(nonsmallcelllungcancer,NSCLC)的近期疗效及不良反应。方法对48例局部晚期NSCLC患者用全身伽玛刀放疗,同时配合全身化疗,每位病人至少完成2个周期化疗,末次化疗结束后4周以上评价疗效。结果完全缓解(CR)为14.6%,部分缓解(PR)77.1%,总有效率(CR+PR)91.7%;血液毒性主要为白细胞下降,总发生率100%,其中3、4度白细胞下降率为66.7%;放射性食管炎的发生率为8.3%,放射性肺炎为14.6%,均为1、2度。结论全身伽玛刀配合化疗治疗局部晚期NSCLC近期疗效满意,其毒副反应患者可以耐受,无治疗相关性死亡。
出处 《广西医学》 CAS 2005年第6期840-842,共3页 Guangxi Medical Journal
  • 相关文献

参考文献9

  • 1Le Cesne A , Arriagada R , Grunenwald D , et al. New therapentic strategies and current research in inoperable locally advanced non small cell lung cancer[J] .Bull Cancer, 1997,84(4):413~419.
  • 2Fietkau R. Concomitant radioche motherapy of advanced non small cell lung cancer[J]. Lung Cancer ,2001 ,33(Suppl 1 ) :65 ~S76.
  • 3Chandra PB . Combined wodality therapy for unresectable stage Ⅲ non small cell lung cancer[J]. Chest ,2000 , 117(Suppl): 127 ~ 132.
  • 4Albain KS,Crowley JJ,Turrisi AT 3rd, et al . Concurrent cisplatin .etoposide. and chest radiotherapy in pathologic stage Ⅲ B non small cell lung cancer: a Southwest Oneology Group phase Ⅱ study .SWOG 9019[J].J Chin Oncol, 2002, 20(16):3 455~3 460.
  • 5Chen LM , Ignacio L , Jacobs R , et al. Results of a phase Ⅱ concurrent chemoradiotherapy study using three-dimensional couformal radiotherapy with cisplatin and oral etoposide in stage Ⅲ non-small-cell lung cancer [J]. Radiat Oncol Investig, 1999,7( 1 ) :49.
  • 6吴开良,蒋国樑.适形放射治疗的研究现状[J].中华放射肿瘤学杂志,2001,10(1):65-67. 被引量:34
  • 7Armstrong J , Mc Gibuey C . The impact of three-dimensional radiation on the treatment of non small cell lung cancer[J]. Radiother Oncol,2000,56(2): 157~167.
  • 8Michele S,Stanley D, Ann B, et al . Coutimuous, hyperfractionated, accelerated radiotherapy(CHART) Versus conventional radiotherapy in non small cell lung cancer: mature data from the randomised multicentre trial[J]. Radiother Oncol, 1999,52 (2): 137~ 148.
  • 9崔岚,王平全.抗肿瘤药物喜树碱衍生物的研究现状及前景[J].中国药房,2000,11(1):42-43. 被引量:17

二级参考文献27

  • 1[1]Rothenberg ML.Efficacy and toxicity of irinotecan in patients with colorectal cancer[J].Semin Oncol,1998,25(5 suppl 11):39.
  • 2[2]Miya T, Fujikawa R, Fukushima J,et al.Bradycardia induced by irinotecan:a case report[J].Jpn J Clin Oncol,1998,28(11):709.
  • 3[3]Rivory LP,Chatelut E,Canal P,et al. Kinetics of the in vivo interconversion of the carboxylate and lactone for-ms of irinotecan(CPT-11)and of its metabolite SN-38 in patients[J].Cancer Res,1994,54(24):6 330.
  • 4[4]Cunningham D,Pyrhonen S,James RD,et al.Random-ised trial of irinotecan plus supportive care versus sup-portive care alone after fluorouracil failure for patients with metastatic colorectal cancer[J].Lancet,1998,352(9138):1 413.
  • 5[5]Rougier P,Van Cutsem E,Bajetta E,et al.Randomised trial of irinotecan versus fluorouracil by continuous in-fusion after fluorouracil failure in patients with metas-tatic colorectal cancer[J].Lancet,1998,352(9138):1 407.
  • 6[6]Rowinsky EK,Baker SD,Burks K,et al.High-dose to-potecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer:a phaseⅡ and pharmacodynamic study[J].Ann Oncol,1998,9(2):173.
  • 7[7]Perez Soler R,Fossella FV,Glisson BS,et al.PhaseⅡstudy of topotecan in patients with advanced non-sm-all-cell lung cancer previously untreated with chemo-therapy[J].J Clin Oncol,1996,14(2):503.
  • 8[8]Gerrits CJ,Burris H,Schellens JH,et al.Oral topotecan given once or twice daily for ten days:a phase I pharmacology study in adult patients with solid tumors[J].Clin Cancer Res,1998,4(5):1 153.
  • 9[9]Perez Soler R,Glisson BS,Lee JS,et al.Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan[J].J Clin Oncol,1996,14(10):2 785.
  • 10[10]Langevin AM,Casto DT,Thomas PJ,et al.Phase I trial of 9-aminocamptothecin in children with refractory solid tumors:a pediatric oncology group study[J].J Clin Oncol,1998,16(7):2 494.

共引文献49

同被引文献40

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部